AI-guided molecular simulations to design better medicines
From atoms to mechanisms - Artificial Intelligence augmented molecular simulations for mechanistic ligand design
This project uses AI-enhanced computer simulations to design drugs that account for changing protein shapes, aiming to help people who need more precise targeted medicines like some cancer patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project ID | NIH-11376346 on NIH RePORTER |
What this research studies
Researchers run AI-integrated molecular dynamics simulations to watch how disease-related proteins move and change shape over time. They combine ideas from statistical mechanics, advanced sampling algorithms, and AI methods adapted from neural information processing and natural language processing to capture rare events such as drug unbinding and conformational shifts. The team focuses on designing inhibitors for tyrosine kinases and studying model riboswitches to learn mechanistic rules that can be applied broadly. The goal is to automate and scale these methods so they can speed up discovery of better drug candidates.
Who could benefit from this research
Good fit: People with conditions driven by tyrosine kinase dysfunction (for example certain types of cancer) would be most likely to benefit or be future candidates for therapies developed from this work.
Not a fit: Patients with conditions unrelated to protein-targeted drugs or those needing immediate clinical treatments are unlikely to receive direct benefits from this computational research in the short term.
Why it matters
Potential benefit: If successful, this work could accelerate discovery of more effective, longer-lasting, and more selective drugs for diseases driven by proteins like tyrosine kinases.
How similar studies have performed: Traditional structure-based computer-aided drug design has led to approved medicines, but combining AI with dynamic molecular simulations for mechanistic ligand design is relatively new and still exploratory.
Where this research is happening
College Park, United States
- Univ of Maryland, College Park — College Park, United States (Active)
Researchers
- Principal investigator: Tiwary, Pratyush — Univ of Maryland, College Park
- Study coordinator: Tiwary, Pratyush
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.